generated summary

Ketogenic Carnivore as a Cancer Therapy

  • For stage IV breast cancer with a prognosis under five years, a high-fat, animal-based ketogenic diet is beneficial. Strict carnivore isn't essential; carbohydrate restriction, ketosis, and animal fats are important.
  • Meat and animal fats produce the best study outcomes. Some mouse ketogenic experiments use Crisco or hydrogenated vegetable oils and yield poor biomarkers; ketosis does not eliminate the damaging effects of those fats.
  • Triple-negative breast cancer has responded particularly well to ketogenic metabolic therapy [1], and dozens of studies across several cancers show improvements in survival and other outcomes.
  • Cancer is fundamentally a mitochondrial metabolic disease, not a genetic disorder, as Otto Warburg established [2]. DNA supplies blueprints; mitochondria operate as cellular architects and workers. The discovery of DNA shifted attention away from the metabolic origins of cancer.
  • The Warburg effect means cancer cells require approximately 400 times more glucose than normal cells. Lower glucose and higher ketones deprive tumors of energy. The greatest benefits occur with the most aggressive carbohydrate restriction: 200 g/day "low carbohydrate" is not equivalent to 50, 20, 10, or near-zero grams.

Implementing Ketogenic Metabolic Therapy

  • A glucose-ketone index (GKI) below 2, ideally below 1 for periods is the goal [3]. Near-zero-carbohydrate, high-animal-fat eating, energy restriction and fasting can achieve this. Liver and other organs preserve nutrient intake despite lower total energy intake.
  • Fasting can further lower GKI when diet alone is insufficient. Sustained low glucose and elevated ketones maintain metabolic pressure by limiting cancer fuel.
  • Ketosis with chemotherapy and radiation sensitizes cancer cells while protecting healthy tissues and can improve survival. It has no meaningful downside. Oncologists should be consulted, although many dismiss dietary intervention and advise unrestricted eating.

Terminal Non-Small-Cell Lung Cancer and Prednisone

  • Ketogenic studies exist in non-small-cell lung cancer [4], supporting its use in terminal disease with major prednisone-related weight gain. Advanced cancer can still pass a point of no return, and intensive metabolic intervention may fail.
  • Prednisone reduces inflammation and improves breathing but raises blood glucose, can induce diabetes, suppresses anticancer immunity and fuels tumor growth. FDG-PET imaging demonstrates intense glucose uptake in cancer, making hyperglycemia from carbohydrates or steroids an additional fuel source.
  • Steroid withdrawal is not always possible or safe. Severe lung edema risks respiratory failure, while brain-tumor swelling can require steroids around surgery and radiation. Prednisone reduction is desirable only with sufficient improvement in inflammation and breathing; ketosis may facilitate that improvement.
  • If medically possible, ketogenic carnivore eating, GKI below 2 (preferably below 1), restricted eating or fasting, and nutrient-dense organs can be combined with glutamine-targeting drugs. Professor Thomas Seyfried's press-pulse strategy [5] attacks glucose and glutamine availability, with forthcoming coauthored work developing this approach.
  • Remission or reversal is not guaranteed. Some patients are too far advanced, while others improve, survive longer or enjoy better health. The growing literature includes randomized, nonrandomized and self-selected metabolic cancer interventions. Continued metabolic pressure is important after symptoms improve.

References

  1. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer — https://doi.org/10.7759/cureus.1445
  2. On the Origin of Cancer Cells — https://doi.org/10.1126/science.123.3191.309
  3. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer — https://doi.org/10.1186/s12986-015-0009-2
  4. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer — https://doi.org/10.1080/02656736.2019.1589584
  5. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer — https://doi.org/10.1186/s12986-017-0178-2

no comments (yet)

sorted by: hot top controversial new old
there doesn't seem to be anything here